Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder

Nakagawa, Tohru; Taguchi, Satoru; Uemura, Yukari; Kanatani, Atsushi; Ikeda, Masaomi; Matsumoto, Akihiko; Yoshida, Kanae; Kawai, Taketo; Nagata, Masayoshi; Yamada, Daisuke; Komemushi, Yoshimitsu; Suzuki, Motofumi; Enomoto, Yutaka; Nishimatsu, Hiroaki; Ishikawa, Akira; Nagase, Yasushi; Kondo, Yasushi; Tanaka, Yoshinori; Okaneya, Toshikazu; Hirano, Yuki; Shinohara, Mitsuru; Miyazaki, Hideyo; Fujimura, Tetsuya; Fukuhara, Hiroshi; Kume, Haruki; Igawa, Yasuhiko; Homma, Yukio

doi:10.1016/j.urolonc.2016.12.010

Cited by 22 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP is a well-known acute-phase reactant that is significantly elevated in oncological patients with poor prognosis [16] or metastatic disease [17].…”

Section: Discussionmentioning

confidence: 99%

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

Mari

Muto

Maida

et al. 2020

Arab Journal of Urology

View full text Add to dashboard Cite

Objective: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged ≥75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). Patients and methods: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Multivariable regression models were built for the prediction of major postoperative surgical complications, disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM). Results: The median (interquartile range [IQR]) age at surgery was 79 (75-83) years. Major postoperative surgical complications were registered in 41.9% of the patients. The 5-year overall survival, cancer-specific survival and recurrence-free survival rates were 42.4% (95% confidence interval [CI] 34.7-49.9%), 70.3% (95% CI 62.3-76.9%), and 59.8% (95% CI 52.4-66.5), respectively. At multivariable analysis, higher levels of fibrinogen and a modified Glasgow Prognostic Score (mGPS) of 1 and 2 at baseline were independently associated with higher risk of major postoperative complications and of CSM. The inclusion of mGPS and fibrinogen to a standard multivariable model for recurrence and for CSM increased discrimination from 69.4% to 73.0% and from 71.3% to 73.9%, respectively. Preoperative neutrophil-to-lymphocyte ratio of >3 was independently associated with OM (hazard ratio 1.38, 95% CI 1.01-1.77; P = 0.01). Conclusions: In a cohort of elderly patients with UBC treated with RC, fibrinogen and mGPS appeared to be the most relevant prognostic measurements and increased the accuracy of clinicopathological preoperative models to predict major postoperative complications, disease recurrence and mortality.

show abstract

“…CRP is a well-known acute-phase reactant that is significantly elevated in oncological patients with poor prognosis [16] or metastatic disease [17].…”

Section: Discussionmentioning

confidence: 99%

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

Mari

Muto

Maida

et al. 2020

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

“…A summary of recent studies investigating the prognostic role of CRP level in UC is shown in Table . The cut‐off value for high versus low CRP level varied from 0.5 to 8 mg/dL.…”

Section: Serum Protein Markersmentioning

confidence: 99%

“…A summary of recent studies investigating the prognostic role of CRP level in UC is shown in Table 2. [50][51][52][53][54][55] The cut-off value for high versus low CRP level varied from 0.5 to 8 mg/dL. One study by Saito et al evaluated the pre-and post-treatment CRP value.…”

Section: Crp In Ucmentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

“…The OS was analyzed in seven articles with 3,374 patients. 17 , 19 , 21 – 24 , 29 The CSS was investigated in five publications involving 1,086 patients, 16 , 21 – 23 , 26 30dC was inquired into in seven articles with 11,589 patients, 15 , 17 , 18 , 20 , 23 , 25 , 30 and 90dM was explored in six studies with 8,523 patients. 15 , 17 , 18 , 23 , 27 , 28 The cutoff value of pretreatment serum albumin applied in most publications was 3.5 g/dL (the lower limit of normal).…”

Section: Resultsmentioning

confidence: 99%

“…A total of seven articles were included in the meta-analysis of OS in BC patients. 17 , 19 , 21 – 24 , 29 Because of the significant heterogeneity ( I 2 = 60.2%; P < 0.01), random-effects model was used to synthesize the HR for the impact of pretreatment serum albumin on OS. The result showed that patients with decreased pretreatment serum albumin had a significant shorter OS (HR 1.88, 95% CI 1.43, 2.48; P < 0.01; Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis

Li¹,

Cheng²,

Liu³

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundRecently, numerous studies have shown that pretreatment serum albumin can be closely associated with the prognosis of patients with bladder cancer (BC). However, the conclusions regarding this issue are still conflicting. Hence, in this study, we performed a systematic review and meta-analysis to determine the prognostic significance of pretreatment serum albumin in BC patients.Materials and methodsA systematic search was carried out in PubMed, Embase, and Web of Science. A total of 16 studies involving 13,917 patients were included in the current meta-analysis. hazard ratios (HRs) and 95% CIs were pooled to assess the intensity of association. Moreover, heterogeneity, sensitivity analysis and publication bias were explored. All statistical analyses were conducted by STATA 12.0.ResultsOur results suggested that a decreased pretreatment serum albumin level was closely related to a worse overall survival (HR 1.88, 95% CI 1.43, 2.48; P<0.01) and cancer-specific survival (HR 1.65, 95% CI 1.08, 2.52; P=0.02). In addition, from the results of this meta-analysis, it was also observed that a lower pretreatment serum albumin level was linked to higher incidence of postoperative 30-day complication (odds ratio [OR] 1.41, 95% CI 1.03, 1.91; P=0.03) and 90-day mortality (OR 2.51, 95% CI 1.82, 3.48; P<0.01). Furthermore, these findings were demonstrated to be reliable by our sensitivity and subgroup analysis stratified by ethnicity, analysis type, and cutoff value.ConclusionOur results revealed that a lower pretreatment serum albumin level yields a poor long-term prognosis and increases the risks of postoperative complication and mortality in BC patients and can be applied to risk stratification and individualized therapy in BC patients.

show abstract

Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder

Cited by 22 publications

References 21 publications

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer

Role of systemic inflammatory response markers in urological malignancy

The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis

Contact Info

Product

Resources

About